Toxicity and outcome results of RTOG 9311: A phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non–small-cell lung carcinoma-Reference-Cited by-同舟云学术

Toxicity and outcome results of RTOG 9311: A phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non–small-cell lung carcinoma

Published:2005-02 Issue:2 Volume:61 Page:318-328
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Bradley Jeffrey,Graham Mary V.,Winter Kathryn,Purdy James A.,Komaki Ritsuko,Roa Wilson H.,Ryu Janice K.,Bosch Walter,Emami Bahman

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference23 articles.

1. Bradley JD, Zoberi I, Wasserman TH. Normal tissue injury of thoracic organs to radiation therapy. In: Perez CA, Brady LW, editors. Update to principles and practice of radiation oncology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1–15.

2. Clinical dose–volume histogram analysis for pneumonitis after 3D treatment for non–small-cell lung cancer (NSCLC);Graham;Int J Radiat Oncol Biol Phys,1999

3. Radiation pneumonitis as a function of mean dose: An analysis of pooled data of 540 patients;Kwa;Int J Radiat Oncol Biol Phys,1998

4. Predictors of radiation-induced esophageal toxicity in patients with non–small-cell lung cancer treated with three-dimensional conformal radiation therapy;Singh;Int J Radiat Oncol Biol Phys,2003

5. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial;Hayman;J Clin Oncol,2001

Cited by 399 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of Reliable Biomarkers for Radiation Pneumonia Using a Proteomics Approach;J BIOL REG HOMEOS AG;2023

2. Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable, early-stage non-small cell lung cancer;Cost Effectiveness and Resource Allocation;2023-07-28

3. Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options;Current Oncology;2023-03-07

4. Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer;Frontiers in Oncology;2023-02-08

5. Variability of Low-Z Inhomogeneity Correction in IMRT/SBRT: A Multi-Institutional Collaborative Study;Journal of Clinical Medicine;2023-01-23